BioWorld

July 1, 2009

View Archived Issues

Ironed Out at Last: FDA Clears AMAG's Feraheme for Anemia

It was a day late - but AMAG Pharmaceuticals Inc. will hardly end up any dollars short. (BioWorld Today) Read More

Catalyst, Wyeth Partner in $500M Deal for Hemophilia Products

Exclusivity Issue Needlessly Thwarting Biogenerics Debate

Hyperion's Series C Adds $60M for Phase III Trials of HPN-100

Troubled Cell Genesys Signs Merger Deal with BioSante

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

Silhouette of head and brainwith fractal art

ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit

BioWorld

Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley Inc. (NASDAQ:ATAI) ended July 16 at...